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Sequencing efforts led to the identification of so-
matic mutations that could affect the self-renewal
and differentiation of cancer-initiating cells. One
such recurrent mutation targets the binding pocket
of the ubiquitin ligase Fbxw7. Missense FBXW7 mu-
tations are prevalent in various tumors, including
T cell acute lymphoblastic leukemia (T-ALL). To
study the effects of such lesions, we generated ani-
mals carrying regulatable Fbxw7 mutant alleles.
Here, we show that these mutations specifically
bolster cancer-initiating cell activity in collaboration
with Notch1 oncogenes but spare normal hemato-
poietic stem cell function. We were also able to
show that FBXW7 mutations specifically affect the
ubiquitylation and half-life of c-Myc protein, a key
T-ALL oncogene. Using animals carrying c-Myc
fusion alleles, we connected Fbxw7 function to
c-Myc abundance and correlated c-Myc expression
to leukemia-initiating activity. Finally, we demon-
strated that small-molecule-mediated suppression
ofMYC activity leads to T-ALL remission, suggesting
an effective therapeutic strategy.
INTRODUCTION
As next-generation sequencing studies identify novel genetic le-
sions in cancer, it becomes evident that mutations affecting key
regulators of diverse cellular processes ranging frommetabolism
to protein stability are somatically selected in cancer cells
(Downing et al., 2012; Hodis et al., 2012; Zhang et al., 2012). Pre-
sumably, these mutations are selected for because they bestow
cells with tumorigenic properties while sparing their essential1552 Cell 153, 1552–1566, June 20, 2013 ª2013 Elsevier Inc.functions. Heterozygosity of such mutations further complicates
their study, given that it suggests that either small protein
expression differences can have profound outcomes or
missense mutants might have neomorphic and/or dominant-
negative functions. Moreover, mutations rarely act in isolation
but, instead, act in a synergistic manner with additional onco-
genic lesions. Thus, it is vital to study the impact of somatic
missense mutations with genetic models closely mimicking the
corresponding human cancer genotypes and to consider the
in vivo effects of mutational cooperation.
FBXW7 is mutated in a significant portion of human tumors,
including approximately 20% of patients with T cell acute
lymphoblastic leukemia (T-ALL) (Akhoondi et al., 2007; O’Neil
et al., 2007; Thompson et al., 2007). Fbxw7 is a constituent of
the SCF (Skp1-Cul1-F box) ubiquitin ligase complex that con-
trols the degradation and half-life of key cellular regulators,
including Cyclin E, Notch1, c-Myc, and Mcl1 (Crusio et al.,
2010; Wang et al., 2012). Mutations in FBXW7 are predominantly
heterozygous and cluster within the WD40 substrate-binding
domain, specifically affecting three highly conserved arginine
residues (Nash et al., 2001). Although the outcome of expressing
these particular mutations in somatic tissues remains unknown,
monoallelic deletion of Fbxw7 in the hematopoietic system fails
to induce leukemia. Although complete deletion can lead to
T-ALL establishment, albeit with low penetrance (Matsuoka
et al., 2008), the prevailing phenotype of Fbxw7 loss is a progres-
sive bone marrow (BM) failure that eventually leads to fatal ane-
mia. These findings imply that FBXW7missense mutants are not
simply ‘‘dead’’ alleles and could behave differently in normal and
malignant cells. Accordingly, nonsense FBXW7 mutations are
relatively rare in T-ALL (O’Neil et al., 2007; Thompson et al.,
2007). Although the biochemical mechanism behind FBXW7mu-
tations in T-ALL remains unclear, our group and others have
found that these lesions affect the stability of Notch1, the main
T-ALL oncogene, which is mutated in approximately half of
T cell leukemia patients (Weng et al., 2004). In agreement with
this notion, approximately 25% of NOTCH1 mutations in T-ALL
truncate the protein deleting the conserved degron sequence
recognized by Fbxw7. Similar mutations in either NOTCH1 or
FBXW7 genes are also found in a larger number of additional
cancer types, including marginal B cell lymphoma and mela-
noma (Hodis et al., 2012; Rossi et al., 2012), making the thorough
understanding of their function critical for future therapies.
To study the transforming effects of such missense mutations
in vivo, we have generated mice that carry Cre-inducible Fbxw7
heterozygous mutants, mimicking the most common substitu-
tion found in human T-ALL (R465C). Interestingly, in contrast to
previous knockout models, thesemutations did not compromise
normal hematopoietic stem cell (HSC) function but lead to a
marked increase in the proportion of leukemia-initiating cells
(LICs) due to the stabilization of the Fbxw7 substrate c-Myc. Us-
ing animals expressing fluorescent c-Myc fusion proteins
(MycGFP), we were able to show a perfect correlation between
c-Myc stabilization and leukemia-initiating activity. Moreover,
we were able to demonstrate that c-Myc deletion in established
T-ALL specifically ablates LICs and that the inhibition of c-Myc
induction with small-molecule BET inhibitors targeting Brd4 (Fil-
ippakopoulos et al., 2010; Zuber et al., 2011) can suppress the
growth of mouse and human T-ALL cells. Finally, direct c-Myc
and Brd4 gene targets in T-ALL were identified genome wide
and suggested an intriguing transcriptional cooperation between
these factors and Notch1. Altogether, these studies identify
FBXW7R465C as a unique type of somatic mutation, given that
it has the ability to specifically alter cancer-initiating cell activity
without consequence to normal stem cell differentiation.
RESULTS
Generation of Inducible Knockin Models of FBXW7
Missense Mutations
To test the function of FBXW7mutations in vivo, we targeted the
most common recurrent mutation, an arginine-to-cysteine
change at position 465 (468 in the mouse) (Aifantis et al., 2008).
Given that mice that harbor a similar germline mutation in
Fbxw7 die perinatally because of defects in lung development
(Davis et al., 2011), we generated mutant alleles that could be
conditionally activated with the Cre-lox system. Using homolo-
gous recombination, we generated an R468C mutation in the
endogenous Fbxw7 gene and inserted a lox-STOP-lox cassette
in the upstream intron, thereby functioning as a null allele prior
to recombination and as amutant in all lineageswhereCre is acti-
vated (Figure S1A available online). Fbxw7R468Neo/+ pups were
born and developed normally, yet Fbxw7R468Neo/R468Neo mice
were never represented, which was consistent with reports that
Fbxw7-null mice die in utero (Tsunematsu et al., 2004). Mice
were crossed to the pI:pC-inducible Mx1-Cre allele (Ku¨hn et al.,
1995). Recombination was observed in the genomic DNA of
BM cells, and the mutation could be detected in messenger
RNA (mRNA) (Figures S1B–S1C) after pI:pC treatment. Alterna-
tively, to study the effect of the exact human R465C mutation,
we introduced an exogenous human FBXW7R465C comple-
mentary DNA (cDNA) (with an N-terminal FLAG tag) in the ubiqui-
tously expressed elongation factor 1 alpha (Eef1a1) locus
(Klinakis et al., 2009). As with the endogenous mouse Fbxw7mutant, this targeting positioned a lox-STOP-lox cassette
upstream of the mutant cDNA for conditional activation (Fig-
ure S1D). UponCre induction, we could detect robust expression
of a 110 kDa protein by FLAG immunoblot in lysates fromprimary
tissues (Figure S1E). Furthermore, themutant human Fbxw7was
functional and incorporated into the SCF complex, whereas
other components (Skp1 and Cul1) could be coimmunoprecipi-
tated (data not shown). Aswill become evident from the following
studies, both alleles (Fbxw7R468 and Eef1a1mutW7) yield similar
phenotypes. Most of the presented studies will focus on the
Fbxw7R468 endogenous allele (referred as Fbxw7mut).
FBXW7 Mutations Do Not Affect Normal HSC and
Progenitor Differentiation
Previous studies have shown that conditional deletion of Fbxw7
in the adult hematopoietic system leads to a rapid depletion of
HSCs and T cell progenitors (Matsuoka et al., 2008; Thompson
et al., 2008). Given that HSCs provide a long-lived reservoir of
cells with an inherent capacity for self-renewal, it has been
hypothesized that many of the oncogenic lesions found in he-
matopoietic malignancies might arise in HSCs or multipotent
progenitors (Francis and Richardson, 2007; Mohrin et al.,
2010). However, this presents a paradox for FBXW7 mutations
in particular, given that these mutations could be deleterious
for normal hematopoiesis and selected against prior to transfor-
mation. To test the possibility that heterozygous Fbxw7 muta-
tions might be tolerated differently than deletion of one or both
alleles, we assessed HSC function in Fbxw7F/+Mx1-Cre+
(Fbxw7D/+), Fbxw7mut/+Mx1-Cre+, and Fbxw7F/FMx1-Cre+ mice
(Fbxw7D/D). As expected, the frequency and absolute number
of HSCs (LinSca1+c-kit+CD150+CD48) was significantly lower
in Fbxw7D/D in comparison to Fbxw7D/+ BM. However, there was
no decrease in phenotypic HSCs observed in Fbxw7mut/+ mice
(Figures 1A–1B). Also, Fbxw7mut/+ HSCs were more functionally
competent than Fbxw7D/D, given that they generated a greater
number of colonies in colony-forming assays (Figure 1C) and
reconstituted recipient mice to the same extent as Fbxw7D/+
donors upon competitive BM transplantation (Figure 1D).
Moreover, the depletion of early T cell progenitors typically
seen in Fbxw7D/D thymii was also absent in Fbxw7mut/+mice (Fig-
ure 1E), demonstrating that the mutant progenitors could colo-
nize the Fbxw7-deficient thymus and differentiate normally.
Fbxw7-deficient HSCs fail to self-renew primarily because of
an aberrant accumulation of c-Myc protein (Reavie et al.,
2010). To test whether differential c-Myc abundance could ac-
count for the inability of the mutant allele to affect hematopoi-
esis, we determined the level of c-Myc protein in HSC of each
genotype by crossing the Fbxw7mut and Fbxw7F/F Mx1-Cre
strains to a mouse expressing a c-Myc:GFP fusion from the
endogenous Myc locus (MycGFP) (Huang et al., 2008). Intrigu-
ingly, the level of c-Myc stabilization in mutant HSCs was
significantly greater than that ofFbxw7D/+ but still lower than
that observed in Fbxw7-deficient HSCs (Figures 1F–1G). Alto-
gether, these data imply that the intermediate levels of c-Myc
stabilization resulting from a heterozygous Fbxw7 mutation are
tolerated in HSCs, whereas the level of c-Myc in Fbxw7-defi-
cient HSCs surpasses a threshold that is incompatible self-
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Figure 1. Mutant Fbxw7 Does Not Impair HSC Function or T Cell Differentiation In Vivo
(A and B) Representative fluorescence-activated cell sorting (FACS) plots showing the frequency of Linc-kit+Sca-1+ (LSK) BM cells from Fbxw7D/+, Fbxw7mut/+,
or Fbxw7D/D mice 8 weeks after pI:pC injection (A) and the number of phenotypic LT-HSCs (CD150+CD48LSK) recovered (B).
(C) Primary and secondary colonies derived from LSKs sorted from the BM of the indicated genotype.
(D) Frequency of CD45.2+ donor-derived peripheral blood mononuclear cells (PBMCs) in lethally irradiated recipient mice transplanted with 53 105 total BMMCs
from either Fbxw7F/+Mx1Cre+, Fbxw7mut/+Mx1Cre+, or Fbxw7F/FMx1Cre+mice (CD45.2+) mixed at a 1:1 ratio with WT BMMCs (CD45.1+) at 4 and 8 weeks after
transplant. FACS profiling of thymocytes from Fbxw7D/+, Fbxw7mut/+, or Fbxw7D/D mice analyzed 4 weeks after pI:pC injections.
(legend continued on next page)
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FBXW7 and NOTCH1 Mutations Cooperate for the
Induction of Aggressive Leukemia
Although mutations in Fbxw7 are highly prevalent and implicated
in the pathogenesis of T-ALL (O’Neil et al., 2007; Thompson et al.,
2007), it is unknown whether these mutations are sufficient for
leukemia induction in vivo. To address this question, a cohort of
Fbxw7mut/+ or Eef1a1mutW7/+ mice were monitored periodically
by peripheral blood analysis for up to 18 months. Surprisingly,
none of these mutant mice ever exhibited elevated white blood
cell counts in comparison to their wild-type (WT) littermates or
developed leukemia spontaneously (Figure 2A). Moreover, no
other tumors or developmental defects were observed when a
single mutant allele was activated in early-stage embryos with
EIIa-Cre (data not shown). Next, we tested whether Fbxw7
mutationswould act synergisticallywith other knownT-ALLonco-
genes. FBXW7 mutations frequently co-occur with NOTCH1
heterodimerization domain (HD) mutations in human T-ALL
(Grabher et al., 2006). This scenario wasmodeled in vivo by retro-
viral expression of Notch1DE, a truncated form of Notch1 that
is constitutively cleaved in a ligand-independent manner
(Aster et al., 1997) on an Fbxw7+/+, Fbxw7D/+, Fbxw7mut/+, or
Eef1a1mutW7/+ background. Although all four cohorts eventually
succumbed to T-ALL, the cohorts transplanted with either
Fbxw7 mutant developed leukemia at a much shorter latency in
comparison to the Fbxw7+/+ and the Fbxw7D/+ groups (Figure 2A).
The median survival of the Fbxw7mut/+ and Eef1a1mutW7/+ cohorts
was identical. Mice from each group were analyzed at 21 days
after transplant in order to evaluate leukemia progression. The
mutant cohorts presented with a higher proportion of leukemic
blasts, notably larger in size in comparison to their WT counter-
parts, in the peripheral blood and heavier infiltration of peripheral
tissues (Figures 2B and 2C). In addition, a greater proportion of
theseblastswereactively cycling, asexhibitedbymoreprominent
Ki67 staining (Figures 2D and 2E). Because the extent of matura-
tion of T-ALL often correlates with a poorer prognosis (Ferrando
and Look, 2003; Zhang et al., 2012), the expression of surface
markers corresponding to different stages of physiological T cell
development was compared between genotypes. A noticeable
trend in decreased CD4 and, to a lesser extent, CD8 surface
expression was observed in the Fbxw7 mutant leukemias (Fig-
ure 2F), suggesting a more immature (and potentially aggressive)
phenotype.Given thatNotch1 isanFbxw7substrate,we repeated
the presented leukemia-induction experiments using human
Notch1-DPEST mutants (Chiang et al., 2008), which are lacking
the C-terminal region bound by Fbxw7. As seen in Figure 2G,
Fbxw7mut/+Notch1DPEST tumors also developed with significantly
shorter latency, suggesting that additional Notch stabilization
alone could not explain the aggressiveness of the disease.
Initial attempts to serially transplant the disease revealed that
the Fbxw7mut leukemias were more efficient in generating sec-
ondary tumors (Figure 2H). Thus, we hypothesized that the fre-
quency of LICs might be higher within the Fbxw7mut leukemia.
To quantify the LIC frequencies in Fbxw7 mutant or WT T-ALL,(E and F) Histogram (E) and calculated mean fluorescence intensity (F) of GFP me
fusion (MycGFP/+) allele.
Error bars in (B), (C), (D), and (G) indicate mean ± SD. *p < 0.05; **p < 0.01.
See also Figure S1.we transplanted equivalent numbers of GFP+ cells sorted from
leukemias arising from either genotype into secondary recipients
at a range of doses from 104–106 cells per recipient. All of the
mice transplanted with 106 cells, regardless of Fbxw7 status,
eventually developed leukemia. However, the frequency of leu-
kemia in mice that received 2 3 105 or 5 3 104 cells was signif-
icantly higher in the Fbxw7 mutant cohorts (100% versus 11%
and 75% versus 0%, respectively) (Figure 2H). Using limiting
dilution analysis (Buchstaller et al., 2012), we calculated that
the LIC frequency within the Fbxw7 mutant T-ALL was more
than 10-fold higher than in Fbxw7 WT T-ALL (Figure 2I).
FBXW7Mutations Do Not Lead to Genomic Instability or
Cooperate with p53 Loss
Previous studies observed genomic instability in human cancer
cells when FBXW7 was deleted (Grim et al., 2012; Rajagopalan
et al., 2004). To test whether chromosomal abnormalities were
contributing to leukemia development in vivo, we utilized meta-
phase fluorescent in situ hybridization (mFISH) to karyotype
Fbxw7 mutant leukemias. However, the vast majority of tumor
cells had a normal karyotype (Figure S2A). To test for smaller
genomic events, we analyzed DNA from leukemic cells by
array-comparative genomic hybridization (array CGH). Several
Fbxw7mutant orWT leukemiaswere analyzed, andnormal tissue
from donor mice was used as a reference. Between both groups
of samples, the only significant DNA gain or loss consistently
foundwaswithin the Tcra locus (Figure S2B), whichwas in agree-
ment with the identity and developmental stage of the leukemia.
Although neither of these results rule out the possibility of collab-
orating point mutations, genetic instability is unlikely to be
responsible for the more aggressive nature of Fbxw7mutant leu-
kemias. In addition to activating mutations inNotch1, Fbxw7 has
been genetically associatedwith the inactivation of p53 in a num-
ber of tumor models (Grim et al., 2012; Onoyama et al., 2007). To
determine whether loss of p53 could collaborate with our Fbxw7
mutant allele, we transduced Fbxw7+/+, Fbxw7mut/+, or Fbxw7D/D
BM with a retroviral small hairpin RNA (shRNA) targeting Trp53.
The WT or Fbxw7D/D donors generated tumors in recipient
animals with a time of onset and disease phenotype that coin-
cided with the previous genetic models (Figure S2C). However,
the latency of leukemia development was not decreased by the
mutation of Fbxw7, despite the efficient silencing of Trp53 (Fig-
ure S2D). Therefore, there is a clear disparity between Fbxw7-
null and Fbxw7R465C mutants in the requirement for p53
inactivation. Moreover, unlike NOTCH1, TP53 mutations are not
enriched in FBXW7 mutant human T-ALL (Zhang et al., 2012),
thus supporting our findings with the Fbxw7mut animal models.
FBXW7 Mutations Affect c-Myc Protein Half-Life and
Ubiquitylation
Having ruled out genomic instability, we sought to determine the
mechanism by which Fbxw7 mutations confer a greater leuke-
mia initiating capacity to cells uniformly expressing a Notch1asured by FACS in LT-HSCs from mice in (A) and (B) expressing a c-Myc:GFP
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Figure 2. Fbxw7 Mutations Accelerate NOTCH1-Induced T-ALL and Expand the Number of LICs
(A) A Kaplan-Meier (K-M) curve representingmorbidity in recipient mice transplantedwith BM from Fbxw7mut/+,Eef1a1mutW7/+, Fbxw7D/+, or Fbxw7+/+ transduced
with a Notch1DE ires GFP retrovirus. As a control, mice transplanted with Fbxw7mut/+ or Eef1a1mutW7/+ cells not expressing a Notch1DE (Notch1) are shown
(Mantel-Cox log rank test; Fbxw7mut/+ versus Fbxw7+/,+ p < 0.0001; Fbxw7mut/+ versus Fbxw7D/+, p = 0.0056; Fbxw7D/+ versus Fbxw7+/+, p = 0.5617).
(B–E) Peripheral blood and organs were harvested 3 weeks after transplant and prepared for histology.
(B) A Wright-Giemsa stain of peripheral blood.
(C) Hematoxylin and eosin staining of the liver.
(D and E) Ki67 staining of the liver and lung.
(F) Representative FACS plots depicting CD4 and CD8 expression on either Fbxw7mut/+ or Fbxw7+/+ GFP+ cells in the peripheral blood of recipients.
(G) A K-M curve representing morbidity in recipient mice transplanted with BM from Fbxw7mut/+ or Fbxw7+/+ mice transduced with retroviruses expressing
mutant, truncated forms of Notch1 lacking a C-terminal PEST domain, and bearingNOTCH1HD (L1601P and insP12) mutations (L1601P, p = 0.0177; insP12, p =
0.0266).
(H) A fraction of secondary recipients that developed leukemia when transplanted with limiting dilutions of GFP+ splenocytes sorted from either Fbxw7 WT or
mutant T-ALL mice.
(I) A log-log plot and leukemia initiating cell frequency calculated by extreme limiting dilution analysis. Red, Fbxw7mut/+ (1/39,410); black, Fbxw7+/+ (1/498,075).
See also Figures S1 and S2.
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oncogene. The protein half-life of a panel of known substrates
was measured in either Fbxw7WT or mutant Notch1 T-ALL cells
ex vivo (Figure S3A). Of the substrates tested, we noted moder-
ate stabilization of Notch1 and Srebp1 and a very consistent and
significant stabilization of c-Myc (Figure S3A).Myc has an essen-
tial role in cell growth and self-renewal (Eilers and Eisenman,
2008; Murphy et al., 2005) and has previously been implicated
in the pathogenesis of T-ALL as a transcriptional target of Notch1
(Palomero et al., 2006; Sharma et al., 2006). Thus, we focused on
the putative mechanisms of c-Myc stabilization by the mutant
Fbxw7 allele. In an in vitro ubiquitylation assay, the R465Cmuta-
tion renders Fbxw7 incapable of ubiquitylating c-Myc (Fig-
ure S3B). Given that SCF-Fbxw7 complexes have been shown
to dimerize in certain conditions (Welcker and Clurman, 2007),
we hypothesized that Fbxw7 mutations could affect the ability
of Fbxw7mut:Fbxw7WT heterodimers to bind and ubiquitylate
c-Myc. To test this hypothesis, we expressed either Fbxw7WT
or Fbxw7R465C bearing unique epitope tags, isolated dimers,
and quantified binding to endogenous c-Myc. Although a robust
interaction with c-Myc was detected in the WT:WT dimers, bind-
ing to MUT:WT dimers was significantly decreased (Figure S3C).
MUT:MUT Fbxw7 homodimers failed to bind detectable levels of
c-Myc.
Fbxw7-Regulated c-Myc Protein Expression Specifically
Marks LSCs In Vivo
To track c-Myc protein levels during leukemia progression
in vivo, we transplanted either Fbxw7+/+MycGFP/+ or Fbxw7mut/+
MycGFP/+ BM cells transduced with a Notch1DE-ires-mCherry
retroviral vector. Because Myc is a transcriptional target of
Notch1 (Palomero et al., 2006), we expected that the
Notch1DE-transduced population would uniformly express
high levels of MycGFP. However, at earlier time points,
Notch1DE+ cells that had detectable levels of c-Myc were virtu-
ally absent from circulation (Figure S4A) and rare in the spleen
(Figure 3A). Strikingly, this population was typically 10-fold larger
in the Fbxw7 mutant leukemia (Figure 3A). Costaining for T cell
surface markers revealed that MycGFP expression was highest
in the CD4CD8CD25hi (DN3) and ISP8 (CD4CD8+TCRblow)
fractions but was undetectable in CD4+CD8+ (DP) cells. Notably,
the MycGFP+ leukemic cells also had elevated IL-7Ra expression
(Figure S4B). As the leukemia progressed, the MycGFP+ popula-
tion became more abundant, but it never achieved a majority
(Figure S4C). Interestingly, between hematopoietic and
lymphoid organs, the highest frequency of MycGFP+ cells was
consistently observed in the spleen (Figure S4D).
To determine whether theMycGFP+ population was enriched in
LIC activity, 105 Notch1DE+MycGFP+ and Notch1DE+MycGFP
cells were sorted from the spleen of leukemic mice (Figures
S4E–S4F) and transplanted into secondary recipients. Two
weeks after transplant, the cohort transplanted with MycGFP+
cells had significantly greater numbers of leukemic cells in
peripheral blood (Figure 3B). More importantly, the cohort trans-
planted with MycGFP cells exhibited 100% leukemia-free sur-
vival, whereas the MycGFP+ cohort all succumbed to T-ALL by
6 weeks after transplant (Figure 3C). Importantly, secondary
leukemias arising from the MycGFP+ cohort re-established the
heterogeneity of the primary tumor, including both MycGFP+and MycGFP cells (Figure S4G), demonstrating that MycGFP+
cells can self-renew and differentiate—the defining properties
of a cancer stem cell. Altogether, these data define c-Myc pro-
tein abundance a bona fide LIC marker in a T-ALL mouse model
and suggest that this population is heavily dependent on Fbxw7
activity. To test whether this observation translates to human
T-ALL, CD34+ populations enriched for T-ALL LICs (Armstrong
et al., 2009) were purified from human patient samples that carry
NOTCH1 and FBXW7 mutations. In agreement with the mouse
data, non-LIC subsets expressed significantly lower levels of
c-Myc protein in comparison to the CD34+ fraction (Figure 3D)
despite no increase in MYC mRNA (Figure 3E) or cleaved
Notch1. c-Myc levels were higher in samples carrying FBXW7
mutations, further supporting the notion that missense FBXW7
mutations augment c-Myc protein stability in T-ALL.
T-ALL LICs Are Defined by aMyc Gene Expression
Signature
To study this subpopulation enriched in T-ALL LIC activity
further, we sought to determine its underlying molecular signa-
ture using gene expression analysis. Total RNA was isolated
from either MycGFP+ or MycGFP leukemic cells, and gene
expression was determined by microarray analysis (Figure 3F).
The most represented group among the top upregulated genes
included those involved in the mitotic phase of the cell cycle
(Cdc6,Ccnb1,Chek1, Aurkb, andBrca1) and, as expected, tran-
scriptional targets of c-Myc (Cad, Suv39h2, Bcat1, and Pa2g4)
(Kim et al., 2008; Margolin et al., 2009). Also, many genes encod-
ing cell-surface markers (Fas, Slamf1, Il7r, and Cd4), which may
be helpful for further thorough dissection of the LIC population,
differed significantly at the mRNA level between the two popula-
tions. Gene set enrichment analysis (GSEA) was performed in
order to identify gene modules that are enriched within the
MycGFP+ population (Figure 3G). Gene sets pertaining to stem
cell identity, including common genes upregulated in adult and
embryonic stem cell (ESC) populations, as well as a set of
c-Myc-regulated genes in both ESCs and human cancers (Kim
et al., 2008), were highly enriched (Figure 3F). Gene sets associ-
ated with early T cell progenitors (Lee et al., 2004), and undiffer-
entiated tumors (Rhodes et al., 2004) were also enriched. Fbxw7,
on the other hand, was significantly downregulated in the
MycGFP+ population (Figure 3F), suggesting that, in the absence
of mutations, there is a need to transcriptionally downregulate its
activity during leukemic progression (Mavrakis et al., 2011).
Myc Deletion Specifically Targets LICs in an Animal
Model of T-ALL
Given that leukemia-initiating capacity was found to be restricted
to the MycGFP+ population, we tested whether the depletion of
Myc could specifically ablate LIC activity in T-ALL. Primary
T-ALLs were generated from MycF/FMx1-Cre+ or Myc+/+Mx1-
Cre+ donors, and recipients were injected with pI:pC 2 weeks
later, after leukemic cells were detected in the periphery. Our
initial observation was that leukemic burden was decreased in
recipients in which c-Myc expression was deleted (Figure 4A).
Strikingly, the LIC-enriched DN3 subset was almost completely
absent in the Myc-deficient leukemias (Figure 4B), suggesting
that the LIC population absolutely depends on c-Myc functionCell 153, 1552–1566, June 20, 2013 ª2013 Elsevier Inc. 1557
Figure 3. Myc Protein Stability and Expression Defines Leukemia-Initiating Potential in T-ALL
Fbxw7mut/+MycGFP/+ or Fbxw7+/+MycGFP/+ BM was transduced with Notch1DE-ires-mCherry and transplanted into lethally-irradiated recipients.
(A) c-MycGFP in mCherry+ splenocytes derived from either donor measured by FACS 4 weeks after transplant (the frequency of mCherry+ cells expressing both
c-MycGFP and CD25 is shown). Fbxw7+/+ mCherry+ splenocytes from leukemic mice were sorted on the basis of c-MycGFP expression and transplanted into
sublethally irradiated recipients.
(B and C) Frequency of mCherry+ PBMC 3 weeks after transplant (B) and the survival (C) of secondary recipients.
(D and E) Immunoblot for c-Myc and intracellular Notch1 (ICD) (D) and quantitative RT-PCR (qRT-PCR) analysis forMYC transcript (normalized to GAPDH) (E) in
two independent primary human T-ALL xenografts sorted on the basis of CD34 expression. NOTCH1 and FBXW7 mutational status is shown for each patient.
(F) A heat map depicting differentially expressed genes (fold change > 2, p < 0.05) in Notch1DE+c-MycGFP+ versus Notch1DE+c-MycGFP T-ALL cells sorted from
the spleen of three individual mice.
(G) Selected expression signatures found to be enriched in c-MycGFP+ population as determined by GSEA.
See also Figures S3 and S4.
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Figure 4. Genetic Depletion of Myc Expression Abolishes Leukemia-Initiating Activity in T-ALL
(A) Myc+/+Mx1Cre+ or MycF/FMx1Cre+ BM was transduced with Notch1DE and transplanted into lethally irradiated recipients. Notch1DE+ T-ALL cells were
measured in peripheral blood 2 weeks after transplant (top) and 7 days after pI:pC treatment (bottom).
(B) FACS analysis showing the frequency of Notch1DE+ cells expressing CD4 and CD8 (top) and CD4CD8CD25hiIL-7Ra+ (bottom) immunophenotype within
spleen following Cre induction.
(C) Frequency of Notch1DE+ PBMC in secondary recipients of Myc WT and deficient T-ALL cells 2 weeks after transplant. Error bars indicate mean ± SD.
See also Figure S5.in vivo. To test this hypothesis further, we transplanted equal
numbers of Notch1DE+ cells from either the pI-pC-treated
MycF/F or Myc+/+ primary T-ALL and assessed leukemia devel-
opment in secondary hosts. We found that, although the Myc
WT cells effectively generated secondary tumors, no leukemic
cells were detected in the Myc-deficient group (Figure 4C),
demonstrating the absence of functional LICs.
BET Inhibitors Efficiently Suppress Growth of Mouse
and Human T-ALL
Recently, selective BET bromodomain inhibitors were identified
to specifically target BRD4, a transcriptional activator of MYC
(Delmore et al., 2011; Devaiah et al., 2012; Filippakopouloset al., 2010; Mertz et al., 2011; Zuber et al., 2011). One of these
molecules, JQ1, was shown to effectively inhibit the expression
and function of MYC, and it inhibited cell growth in multiple
myeloma and acute myeloid leukemia (Filippakopoulos et al.,
2010; Mertz et al., 2011). To determine whether the inhibition
of BRD4 could similarly lead to growth inhibition in T-ALL, we
initially compared retroviral shRNA knockdown of Myc and
Brd4 in Notch1+ mouse T-ALL cell lines. A significant loss of rep-
resentation over time was observed in populations expressing
shRNA targeting either gene (Figure S5A). The growth effect
induced by the MYC hairpins was on target, given that comple-
mentation with non-RNA interference (RNAi)-targeted MYC
cDNA restored their growth potential (Figure S5B).Cell 153, 1552–1566, June 20, 2013 ª2013 Elsevier Inc. 1559
Figure 5. BET Bromodomain Inhibition
Broadly Impacts the Growth of Human
T-ALL
(A–C) A dose response curve showing the growth
of a CUTLL1 human T-ALL line (FBXW7 WT)
treated with increasing concentrations of JQ-1 or
vehicle. The frequency of cells that incorporated
BrdU during a 1 hr pulse (B) or stained positive for
Annexin V (C) was determined after treatment with
JQ-1 for 48 hr.
(D) Growth of human T-ALL lines treated with GSI
(Compound E) or JQ-1 in vitro after 4 days relative
to vehicle-treated controls.
(E) Immunoblot for Notch1 ICD and c-Myc in
T-ALL lines treated with inhibitors.
(F) We treated 720 cells transduced with pMIG,
either empty or bearing a c-Myc cDNA, for 72 hr
withJQ-1at the indicatedconcentrationandpulsed
themwith BrdU for 1 hr, and the frequency of GFP+
cells in S phasewas determined by flow cytometry.
Error bars indicate mean ± SD. *p < 0.05; **p <
0.01; ***p < 0.001.
See also Figure S6.To start addressing the putative leukemia-targeting properties
of BET inhibitors, we tested the growth of human T-ALL lines in
the presence of varying concentrations of JQ-1 in vitro (Fig-
ure 5A). A significant decrease in cell growth was observed after
4 days of JQ-1 treatment in a dose-dependent manner. BrdU
incorporation assays and AnnexinV staining suggested that
JQ-1 treatment resulted primarily in growth arrest rather than
apoptosis (Figures 5B–5C). Given that previous work has shown
that FBXW7 mutations conferred resistance to gamma-secre-
tase inhibitors (GSIs) (Real et al., 2009; Thompson et al., 2007),
response to JQ-1 or GSI (Compound E) was compared in
FBXW7 mutant or WT T-ALL lines (Figure 5D). As expected,
GSI treatment inhibited the growth of HPB-ALL cells (WT
FBXW7) but was significantly less effective in CEM or Jurkat
T cells (both FBXW7 mutants). However, all T-ALL lines were
unable to grow in the presence of JQ-1. The observed growth ar-
rest was due, at least in part, to a loss of c-Myc, given that JQ-1
treatment resulted in a significant reduction in c-Myc protein
expression in all T-ALL lines tested (Figure 5E) and overexpres-1560 Cell 153, 1552–1566, June 20, 2013 ª2013 Elsevier Inc.sion of c-Myc partially restored prolifera-
tion of the treated cells (Figure 5F). Alto-
gether, these results show that BET
bromodomain inhibitors are an appealing
alternative to GSI treatment because they
are able to target T-ALL cells irrespective
of FBXW7 mutations.
In order to determine the in vivo effi-
cacy of BET inhibitors with mouse
T-ALL models, it was necessary to estab-
lish an in vitro system to maintain
and expand c-MycGFP+ LICs. Primary
Notch1DE+c-MycGFP+ splenocytes lose
expression of c-MycGFP and fail to
expand in liquid culture (Figure S5C).
However, when cocultured on OP9 stro-mal line in the presence of IL-7, these cells maintain their expres-
sion of c-MycGFP (Figure S5C) and can be expanded indefinitely.
Upon treatment with JQ-1, expression of c-MycGFP rapidly re-
turns to basal levels (Figure 6A) and the growth of the T-ALL cells
is significantly inhibited (Figure 6B). To study the effect of BET
bromodomain inhibitors on the progression of T-ALL in vivo,
we utilized a derivative of JQ1, CPI203 (Devaiah et al., 2012),
which has shown superior bioavailability with oral or intraperito-
neal (i.p.) administration. The EC50 of CPI203 was nearly 3-fold
lower than JQ-1 (91.2 versus 263 nM) when tested on a primary
mouse T-ALL in vitro (Figure 6B), and this corresponded to a
decrease in Myc mRNA (Figure 6C). To measure the effect of
CPI203 in vivo, two independently derived primary mouse
T-ALL samples, either Fbxw7+/+ or Fbxw7mut/+, were transduced
with a lentiviral luciferase reporter and each transplanted into
two recipient animal groups, one treated with CPI203 (5 mg
kg1, BID) and the other with vehicle, and disease progression
was monitored by in vivo luciferase imaging (IVIS Lumina) (Fig-
ure 6D). A significant and rapid reduction in leukemia burden
Figure 6. BET Bromodomain Inhibitors Deplete LICs and Inhibit the Progression of T-ALL Both In Vitro and In Vivo
(A) A histogram depicting c-MycGFP levels in primary Notch1DE ires mCherry+c-MycGFP+ splenocytes cocultured on OP9 stromal cells in the presence of 5 ng/ml
IL-7 and either 200 nM JQ-1 or DMSO.
(B) Growth of primary mouse T-ALL treated with increasing concentrations of JQ-1 or CPI203 for 72 hr. Calculated EC50 for each compound is shown.
(C) Myc mRNA measured by qRT-PCR in primary mouse T-ALL cells treated with CPI203 for 4 hr at the indicated concentration.
(D) Bioluminescent imaging of recipient mice transplanted either Fbxw7+/+ (top) or Fbxw7mut/+ (bottom) Notch1DE leukemias and treated with either CPI203
(5 mg kg1) or vehicle BID for 7 days.
(E) Quantification of total bioluminescent counts, each data point representing an individual mouse, before and after 7 days of the indicated treatment.
Error bars for (B) and (C) indicate mean ± SD for three biological replicates. *p < 0.05; **p < 0.01.
See also Figures S5 and S6.was observed in both the recipient groups treated with CPI203
(Figures 6D–6E), thus demonstrating the therapeutic potential
of this compound for use in vivo.Finally, we tested the responseof primary humanT-ALLpatient
samples (all with activating NOTCH1 mutations ± FBXW7
missense mutations) to both JQ1 and CPI203. Typically, a 2- toCell 153, 1552–1566, June 20, 2013 ª2013 Elsevier Inc. 1561
3-fold reduction in cell growth occurred upon treatment with
either compound across all genotypes (Figure S6A). Similarly to
what was observed in the cell lines, this effect could be attributed
mainly to cell-cycle arrest (Figure S6B), although amodest induc-
tion of apoptosis was also observed in two of the samples (Fig-
ure S6C). Altogether, these data indicate significant potential
for BET inhibitors for clinical use in the treatment of T-ALL.
BET Inhibitors Target the Notch and Myc Oncogenic
Transcriptional Program
Brd4 functions as a chromatin reader by binding acetylated his-
tones and recruiting effectors of transcriptional elongation,
thereby promoting gene activation (Hargreaves et al., 2009).
Thus, we hypothesized that Brd4 inhibition might have pro-
found effects on T-ALL gene expression. High-throughput RNA
sequencing (RNA-seq) was performed in CUTLL1 cells after
treatment with inhibitor to assess immediate consequences on
transcription genome wide. A total of 1,696 genes were downre-
gulated, and 1,287 genes were upregulated upon JQ-1 treat-
ment for 12 hr (400 nM) in comparison to vehicle-treated control
(Max FPKM > 5, fold change > 1.3, q < 0.05) (Figure 7A). Interest-
ingly, 28% of genes downregulated upon JQ-1 treatment were
also overexpressed in the MycGFP+ LIC population in our mouse
T-ALL model (Figure 3F). High-throughput chromatin immuno-
precipitation sequencing (ChIP-seq) for c-Myc and Brd4 was
performed in CUTLL1 cells to assess their genome-wide occu-
pancy. A total of 6,335 genes had significant c-Myc binding,
and 6,874 genes showed Brd4 occupancy. Using available
Notch1 and Rbpj ChIP-seq data (Wang et al., 2012), we
compared the 7,526 genes also bound by both of these factors.
A significant fraction of all occupied genes (3,282 of 9,453)
showed binding for all three of these factors, suggesting an over-
lapping regulatory network (Figure 7B). As expected, a large
portion of genes that were downregulated upon JQ-1 treatment
also showed high promoter-read density for Brd4, c-Myc, or
Notch1 (Figure 7C). Accordingly, a specific loss of Brd4 binding
is observed at target gene promoters and enhancers (Figure S7),
and this loss is to a greater extent than Brd2, demonstrating
some specificity of BET inhibition. In order to investigate the
impact of c-Myc and Brd4 binding on direct targets of Notch
and Rbpj, we categorized expressed genes (FPKM > 5) on the
basis of the presence of all three factors, c-Myc, Notch1 only,
or Notch1 alone. We found that genes with Brd4, c-Myc, and
Notch1 binding have significantly higher expression than those
with Notch binding alone. Genes with Brd4, c-Myc, and Notch1
binding or c-Myc and Notch1 binding also showed significantly
higher RNA PolII density at their promoters, implying that the
presence of c-Myc and Brd4, in addition to Notch1 at promoters,
enhances transcriptional activity. Altogether, these data suggest
that, especially in the context of FBXW7 mutations, higher
thresholds of c-Myc work together with Notch1 activation to
amplify a subset of genes critical for leukemic transformation.
DISCUSSION
The presented study sheds light on the selection of FBXW7
mutations during the evolution of leukemia genomes and the sig-
nificant bias for missense (but fewer nonsense, insertion, or dele-1562 Cell 153, 1552–1566, June 20, 2013 ª2013 Elsevier Inc.tion) mutations in human T-ALL. The differential function of
FBXW7mutations could be explained by the existence of distinct
thresholds of c-Myc expression between normal and malignant
stem cells. This observation reveals a potential therapeutic win-
dow for the modulation of Fbxw7 and Myc activity in the treat-
ment of human cancers. Indeed, we were able to show that
Myc deletion suppresses established T-ALL by eliminating
LICs and that pharmacologic targeting of c-Myc induction
restricted the growth of human and mouse T-ALL, including
those that carry FBXW7 mutations and are resistant to Notch
inhibition.
Another important finding illustrated here is that we are able to
visualize LICs using in vivo genetic fluorescent labeling. Using
the c-MycGFP reporter strain, we were able to demonstrate that
LICs can be purified on the basis of c-Myc protein abundance.
T-ALL LICs have a characteristic surface phenotype, and their
gene expression patterns correlate to gene signatures charac-
teristic of earlier stages of differentiation, including HSCs and
ESCs. Interestingly, a large proportion of these LIC-specific
genes are bound by c-Myc and Notch1, both of which are key
oncogenes in T-ALL. Brd4 is also present at most of these loci,
a finding that can explain the therapeutic efficacy of BET inhibi-
tors. Moreover, we observed that c-Myc expression directly
correlated to LIC populations in vivo. Accordingly, human
T-ALL LIC-enriched populations also express high levels of
c-Myc protein, and FBXW7 mutations lead to significant c-Myc
stabilization, suggesting that this mechanism is evolutionarily
conserved. However, this is not a universal characteristic of
tumor-initiating cell populations. Indeed, we have recently per-
formed studies using animal models of BCR-ABL-driven chronic
myelogenous leukemia, a prototypic LIC-driven disease. In this
leukemia model, c-Myc expression does not define the cell pop-
ulation that has the ability to initiate and propagate disease
(Reavie et al., 2013), suggesting that different oncogenes and
cellular settings could have distinct requirements for c-Myc
expression and function.
Although c-Myc is critical in the development of a wide range
of tissues, recent studies have suggested that c-Myc inhibition is
surprisingly well tolerated, at least in preclinical animal studies
(Soucek et al., 2008). Initially, the inhibition of the Notch pathway
with GSIs was a promising therapeutic approach, but it has pre-
sented considerable challenges (gastrointestinal toxicity and
acquisition of resistance, for example) for its adaptation in the
clinic. Here, we show that genetic inactivation of Myc in estab-
lished T-ALL specifically targeted the LIC fraction, eventually
leading to tumor regression and loss of LIC self-renewal. Simi-
larly, treatment of human T-ALL lines and primary leukemic cells
with BET inhibitors (JQ1 and CPI203) completely suppressed
c-Myc response, leading to rapid growth arrest. Unlike GSI treat-
ment, this effect is irrespective of FBXW7 status, suggesting
such compounds could have broader applications across tumor
genotypes. It remains to be seen whether BET inhibition will be
as efficient for the treatment of either relapsed T-ALL or highly
aggressive T-ALL subtypes, including early T cell progenitor
T-ALL, which is also resistant to Notch pathway inhibition (Zhang
et al., 2012).
The combination of disease modeling to whole-genome and
transcriptome studies lead to findings that could have major
Figure 7. BRD4 Inhibition Reduces the Expression of Genes Directly Regulated by MYC and NOTCH1
(A)Heatmaps showing genes significantly downregulated upon treatment ofCUTLL1cellswith JQ-1 (400 nM) for 12hr in comparison to vehicle treated asdetermined
by high-throughput RNA-seq. Eachcolumn represents a biological replicate. ChIP-seq signal density heatmaps (right) showBrd4, c-Myc,Notch1, and total RNAPolII
atgene locidepicted in thegeneexpressionheatmap.GenesareclusteredbasedonBrd4,c-Myc,andNotch1signaldensity.Scale represents readspermillion (RPM).
(B) A Venn diagram showing the overlap of total genes bound by Brd4, c-Myc, and Notch1 in CUTLL1 cells.
(C) Box plots showing Log2FPKM values (left) or promoter PolII density (right) for genes bound by combinations of Brd4, c-Myc, and Notch. Whiskers represent
the upper and lower limits of the range. Boxes represent the first and third quartile, and the line represents the median.
(D) Representative ChIP-seq tracks for three gene loci: IL7R, NPM1, and CDK4. The scale corresponds to RPM.
See also Figure S7.implications for the understanding of oncogenic (Notch andMyc)
interactions and their role in gene expression regulation and
cancer initiation. Our studies show that Notch1 is not sufficient
to induce or maintain transplantable T-ALL in the absence ofc-Myc. Interestingly, we demonstrate that the majority of LIC-
specific genes are bound by both transcription factors, but
deletion of Myc can abrogate LIC activity. In agreement to this
notion, it has been shown in vitro that MYC overexpressionCell 153, 1552–1566, June 20, 2013 ª2013 Elsevier Inc. 1563
can induce resistance to Notch pathway inhibition (Weng et al.,
2006). Thus, we hypothesize that Notch1 acts as a pioneering
factor, influencing lineage commitment and the activity of epige-
netic regulators (Ntziachristos et al., 2012), altering the chro-
matin structure of its transcriptional targets to a more permissive
state. When c-Myc becomes expressed and stabilized (because
of the mutation or downregulation of FBXW7), it can bind to
newly accessible E box motifs, thereby amplifying established
gene-expression programs (Figure 7C). These studies support,
in an in vivo tumor model, the recently postulated ‘‘MYC
transcriptional amplification’’ hypothesis (Lin et al., 2012; Nie
et al., 2012). They also prove that this transcriptional amplifica-
tion mode has in vivo consequences in cancer initiation and
can be pharmacologically targeted. Finally, our studies show
that such key transcriptional responses can be posttranslation-
ally regulated and that oncogenic events invent ways to hijack
them, as shown with in vivo modeling of the FBXW7 missense
mutations.
EXPERIMENTAL PROCEDURES
Mice
c-Myc GFP knockin and Myc conditional knockout mice were as described
previously (de Alboran et al., 2001; Huang et al., 2008). Fbxw7 knockin mutant
mice were generated by the insertion of a loxP-flanked splice acceptor PGK-
NEO cassette with three polyA sites in the intronic sequence between exons
10 and 11, and a CCG-to-GCA point mutation was introduced by PCR muta-
genesis in the opposite strand at a coding sequence corresponding to R468.
Eef1a1 human FBXW7R465C mice were generated by introducing an R465C
mutation into an N-terminally FLAG M2-tagged human FBXW7 alpha cDNA
and subcloning this sequence into an Eef1a1 lox-STOP-lox targeting vector,
as described previously (Buonamici et al., 2009). Inducible Cre recombinase
expression was achieved in Mx1-Cre mice by three consecutive i.p. injections
of poly(I):poly(C) (15 mg kg1, GE Healthcare). CPI203 (Constellation Pharma-
ceuticals) was dissolved in 5%DMSOand 10%hydroxypropyl-beta cyclodex-
trin and administered by i.p. injection twice daily at 5 mg kg1. All animal
experiments were done in accordance with the guidelines of the NYU School
of Medicine or the Columbia University Institutional Animal Care and Use
Committee.
Bone Marrow Transduction and Transplantation
BMwas enriched for hematopoietic stem and progenitor cells by the magnetic
selection of cells expressing c-kit (STEMCELL Technologies) cultured in the
presence of 50 ng/ml SCF, 50 ng/ml Flt3 ligand, 10 ng/ml IL-3, and 10 ng/ml
IL-6 and infected with concentrated retroviral supernatants after 24 and
48 hr. Transduction efficiency was determined by reporter fluorescence at
96 hr, and total or sorted populations were transferred via retroorbital injection
into irradiated (1,100 rad) congenic recipients along with 2 3 105 unfractio-
nated bone marrow mononuclear cells (BMMCs) for hemogenic support. Sub-
lethally irradiated (450 rad) mice were used for secondary transplants. For
Notch1 T-ALL induction, 5 3 104 Notch1DE GFP+ BM cells were transferred
per recipient, unless otherwise stated.
In Vitro Drug Treatments
Human and mouse T-ALL lines were grown in complete RPMI media (supple-
mented with 10% fetal bovine serum, penicillin and streptomycin, glutamine,
and 55 mM b-mercaptoethanol). Primary mouse T-ALL were cocultured
with OP9 stromal cells in Opti-MEM supplemented with 10% fetal bovine
serum, 5 ng/ml IL-7, penicillin and streptomycin, glutamine, and 55 mM b-mer-
captoethanol and passaged every 3–4 days onto a fresh feeder layer. JQ1
(Cayman Chemical) or Compound E (Alexis Biochemicals) prepared in
DMSO was added to the cultures, and the media was replaced every 24 hr.
BrdU (10 mM) was added for a 1 hr pulse, and incorporation into DNA was
determined by using the BrdU Flow Kit (BD PharMingen).1564 Cell 153, 1552–1566, June 20, 2013 ª2013 Elsevier Inc.Chromatin Immunoprecipitation
ChIP-seq was performed in CUTLL1 cells with rabbit polyclonal antibodies
against c-Myc (N-262, Santa Cruz Biotechnology), Brd2 (Bethyl Laboratories,
A302-583A), or Brd4 (Bethyl Laboratories, A301-985A) (5 mg per i.p. injection)
as described previously (Ntziachristos et al., 2012). Peak calling was per-
formed with MACS1.4, allowing only one duplicate read. For Notch1, we
considered only peakswith p < 103 107. For c-Myc and Brd4, we considered
peaks with p < 10 3 105. Peak annotation was performed with a Cis-regula-
tory element annotation system. Genes were considered bound if a peak was
present within 2 kb of the transcription start site.
Statistical Analysis
The means of each data set were analyzed using a Student’s t test with a two-
tailed distribution and assuming equal sample variance.
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